Advertisement

Archives of Osteoporosis

, Volume 7, Issue 1–2, pp 25–30 | Cite as

An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis

  • S. Lekamwasam
  • J. D. Adachi
  • D. Agnusdei
  • J. Bilezikian
  • S. Boonen
  • F. Borgström
  • C. Cooper
  • A. Diez Perez
  • R. Eastell
  • L. C. Hofbauer
  • J. A. Kanis
  • B. L. Langdahl
  • O. Lesnyak
  • R. Lorenc
  • E. McCloskey
  • O. D. Messina
  • N. Napoli
  • B. Obermayer-Pietsch
  • S. H. Ralston
  • P. N. Sambrook
  • S. Silverman
  • M. Sosa
  • J. Stepan
  • G. Suppan
  • D. A. Wahl
  • J. E. CompstonEmail author
  • for the Joint IOF–ECTS GIO Guidelines Working Group
Supplement Article

Abstract

The use of glucocorticoids in the treatment of medical disorders can lead to rapid bone loss and increased risk of fragility fracture. Updated clinical guidelines are needed that accommodate recent advances in fracture risk assessment and new pharmacological interventions to reduce fracture risk. This document serves as an appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis.

Keywords

Glucocorticoids Bone mineral density Fracture FRAX Bone protective therapy 

Notes

Conflicts of interest

None.

References

  1. 1.
    Díez-Pérez A, Hooven FH, Adachi JD et al (2011) Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49(3):493–498PubMedCrossRefGoogle Scholar
  2. 2.
    American College of Rheumatology ad hoc Committee on Glucocorticoid-induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503CrossRefGoogle Scholar
  3. 3.
    Hoes JN, Jacobs JW, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66:1560–1567PubMedCrossRefGoogle Scholar
  4. 4.
    Nawata H, Soen S, Takayanagi R et al (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109PubMedCrossRefGoogle Scholar
  5. 5.
    Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians, LondonGoogle Scholar
  6. 6.
    Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:S1–S34PubMedGoogle Scholar
  7. 7.
    Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8–19PubMedCrossRefGoogle Scholar
  8. 8.
    Geusens PP, Lems WF, Verhaar HJ, Leusink G, Goemaere S, Zmierczack H, Compston JE (2006) Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract 12:539–548PubMedCrossRefGoogle Scholar
  9. 9.
    Gourlay M, Franceschini N, Sheyn Y (2007) Prevention and treatment strategies for glucocorticoid-induced osteoporosis. Clin Rheumatol 26:144–153PubMedCrossRefGoogle Scholar
  10. 10.
    Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arth Care Res 62:1515–1526CrossRefGoogle Scholar
  11. 11.
    Lekamwasam S, Adachi JD, Agnusdei D, et al.; for the Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. doi: 10.1007/s00198-012-1958-1
  12. 12.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRefGoogle Scholar
  13. 13.
    Hoes JN, Jacobs JW, Hulsmans HM, De Nijs RN, Lems WF, Bruyn GA, Geusens PP, Bijlsma JW (2010) High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. Clin Exp Rheumatol 28:354–359PubMedGoogle Scholar
  14. 14.
    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705–1714PubMedCrossRefGoogle Scholar
  15. 15.
    Hozuki T, Imai T, Tsuda E et al (2010) Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study. Intern Med 49:371–376PubMedCrossRefGoogle Scholar
  16. 16.
    Reid DM, Devogelaer JP, Saag K, HORIZON investigators et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263PubMedCrossRefGoogle Scholar
  17. 17.
    Burshell AL, Moricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH (2010) Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46:935–939PubMedCrossRefGoogle Scholar
  18. 18.
    Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K (2010) Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 37:141–148PubMedCrossRefGoogle Scholar
  19. 19.
    Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20:2095–2104PubMedCrossRefGoogle Scholar
  20. 20.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: 36-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355PubMedCrossRefGoogle Scholar
  21. 21.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  • S. Lekamwasam
    • 1
  • J. D. Adachi
    • 2
  • D. Agnusdei
    • 3
  • J. Bilezikian
    • 4
  • S. Boonen
    • 5
  • F. Borgström
    • 6
  • C. Cooper
    • 7
    • 8
  • A. Diez Perez
    • 9
  • R. Eastell
    • 10
  • L. C. Hofbauer
    • 11
  • J. A. Kanis
    • 12
  • B. L. Langdahl
    • 13
  • O. Lesnyak
    • 14
  • R. Lorenc
    • 15
  • E. McCloskey
    • 10
  • O. D. Messina
    • 16
  • N. Napoli
    • 17
  • B. Obermayer-Pietsch
    • 18
  • S. H. Ralston
    • 19
  • P. N. Sambrook
    • 20
  • S. Silverman
    • 21
  • M. Sosa
    • 22
  • J. Stepan
    • 23
  • G. Suppan
    • 24
  • D. A. Wahl
    • 25
  • J. E. Compston
    • 26
    Email author
  • for the Joint IOF–ECTS GIO Guidelines Working Group
  1. 1.Centre for Metabolic Bone Diseases, Department of Medicine, Faculty of MedicineGalleSri Lanka
  2. 2.Division of Rheumatology, Department of MedicineMcMaster UniversityHamiltonCanada
  3. 3.Eli Lilly and Co.FlorenceItaly
  4. 4.Columbia University College of Physicians and SurgeonsNew YorkUSA
  5. 5.Division of Gerontology and Geriatrics and Center for Musculoskeletal Research, Department of Experimental MedicineLeuven UniversityLeuvenBelgium
  6. 6.Quantify Research and LIME/MMCKarolinska InstitutetStockholmSweden
  7. 7.MRC Lifecourse Epidemiology UnitUniversity of Southampton, Southampton General HospitalSouthamptonUK
  8. 8.NIHR Musculoskeletal Biomedical Research Unit, Institute of Musculoskeletal SciencesUniversity of OxfordOxfordUK
  9. 9.Hospital del Mar-IMIM-Universitat AutónomaBarcelonaSpain
  10. 10.Academic Unit of Bone MetabolismUniversity of Sheffield and NIHR Musculoskeletal Biomedical Research Unit, Sheffield Teaching Hospitals NHS TrustSheffieldUK
  11. 11.Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine IIIDresden Technical University Medical CenterDresdenGermany
  12. 12.Centre for Metabolic Bone Diseases (WHO Collaborating Centre)University of Sheffield Medical SchoolSheffieldUK
  13. 13.Department of EndocrinologyAarhus University HospitalAarhusDenmark
  14. 14.Russian Association on OsteoporosisYekaterinburgRussia
  15. 15.Department of Biochemistry and Experimental MedicineThe Children’s Memorial Health InstituteWarsawPoland
  16. 16.Department of RheumatologyC. Argerich HospitalBuenos AiresArgentina
  17. 17.Division of EndocrinologyCampus Bio-Medico UniversityRomeItaly
  18. 18.Division of Endocrinology and Metabolism, Department of Internal MedicineMedical University of GrazGrazAustria
  19. 19.Rheumatic Diseases Unit, Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General HospitalUniversity of EdinburghEdinburghUK
  20. 20.University of Sydney-Royal North Shore HospitalSydneyAustralia
  21. 21.Cedars-Sinai/University of CaliforniaLos AngelesUSA
  22. 22.Bone Metabolic UnitUniversity of Las Palmas de Gran Canaria, Investigation Group on Osteoporosis, Hospital University InsularLas Palmas de Gran CanariaSpain
  23. 23.Institute of Rheumatology, Prague, and Charles University, Faculty of Medicine 1PragueCzech Republic
  24. 24.Action for Healthy BonesGrazAustria
  25. 25.International Osteoporosis FoundationNyonSwitzerland
  26. 26.Department of MedicineCambridge University Hospitals NHS Foundation TrustCambridgeUK

Personalised recommendations